ATE236129T1 - Dihydro- und tetrahydrochinolinderivate als medizinisches antioxydans - Google Patents

Dihydro- und tetrahydrochinolinderivate als medizinisches antioxydans

Info

Publication number
ATE236129T1
ATE236129T1 AT99402624T AT99402624T ATE236129T1 AT E236129 T1 ATE236129 T1 AT E236129T1 AT 99402624 T AT99402624 T AT 99402624T AT 99402624 T AT99402624 T AT 99402624T AT E236129 T1 ATE236129 T1 AT E236129T1
Authority
AT
Austria
Prior art keywords
alkyl
optionally substituted
cycloalkyl
aryl
heterocycloalkyl
Prior art date
Application number
AT99402624T
Other languages
English (en)
Inventor
Patrick Casara
Gilbert Dorey
Pierre Lestage
Brian Lockhart
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE236129T1 publication Critical patent/ATE236129T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
AT99402624T 1998-10-23 1999-10-22 Dihydro- und tetrahydrochinolinderivate als medizinisches antioxydans ATE236129T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9813306A FR2784988B1 (fr) 1998-10-23 1998-10-23 Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ATE236129T1 true ATE236129T1 (de) 2003-04-15

Family

ID=9531911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99402624T ATE236129T1 (de) 1998-10-23 1999-10-22 Dihydro- und tetrahydrochinolinderivate als medizinisches antioxydans

Country Status (20)

Country Link
US (1) US6350759B1 (de)
EP (1) EP0995743B1 (de)
JP (1) JP3159971B2 (de)
KR (1) KR100421074B1 (de)
CN (1) CN1255493A (de)
AT (1) ATE236129T1 (de)
AU (1) AU753044B2 (de)
BR (1) BR9905587A (de)
CA (1) CA2287046C (de)
DE (1) DE69906445T2 (de)
DK (1) DK0995743T3 (de)
EA (1) EA003272B1 (de)
ES (1) ES2196742T3 (de)
FR (1) FR2784988B1 (de)
NO (1) NO313590B1 (de)
NZ (1) NZ500574A (de)
PL (1) PL336139A1 (de)
PT (1) PT995743E (de)
SI (1) SI0995743T1 (de)
ZA (1) ZA996667B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
CN1243000C (zh) * 2000-02-11 2006-02-22 研究发展基金会 生育酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
KR100488444B1 (ko) * 2001-12-31 2005-05-11 한국과학기술연구원 퀴놀론 유도체 및 그 제조 방법
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DE60316688T2 (de) * 2002-08-02 2008-07-17 Nereus Pharmaceuticals, Inc., San Diego Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20070037848A1 (en) * 2003-04-03 2007-02-15 Masters Colin L Treatment of neurological conditions
KR20060026052A (ko) * 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
NZ544858A (en) * 2003-06-20 2009-07-31 Univ California Salinosporamides and methods for use thereof
AU2005206560A1 (en) 2004-01-23 2005-08-04 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP2007535559A (ja) 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド [3.2.0]複素環式化合物及びその使用法
MX2007006526A (es) * 2004-12-03 2007-09-19 Dana Farber Cancer Inst Inc Composiciones y metodos para tratamiento de enfermedades neoplasicas.
US7576094B2 (en) * 2004-12-13 2009-08-18 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
BRPI0709474A2 (pt) 2006-04-06 2011-07-12 Nerus Pharmaceuticals Inc sìntese total de salinosporamida a e seus análogos
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
TWI366565B (en) * 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
JP5247667B2 (ja) * 2008-12-05 2013-07-24 大塚製薬株式会社 医薬
KR101053329B1 (ko) 2009-07-09 2011-08-01 삼성전기주식회사 세라믹 전자부품
CN102958919A (zh) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
CN103159676B (zh) * 2011-12-16 2015-07-15 卢忠林 一种式i化合物的制备方法
US8835643B2 (en) 2012-02-23 2014-09-16 Empire Technology Development Llc Molecules, compositions, and methods for light absorption
EP4166141A1 (de) 2014-09-14 2023-04-19 Avanir Pharmaceuticals, Inc. Kombinierungen aus deuteriertem dextromethorphan und chinidin zur behandlung von unruhe und aggressivität beim alzheimer'schen demenz
AU2016229295B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
CN107304184A (zh) * 2016-04-18 2017-10-31 诺华丝国际股份有限公司 用于从取代的1,2‑二氢喹啉除去污染物的方法
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
EP3565812B1 (de) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin-bindende substanzen und therapeutische verwendung davon
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
CN109553575B (zh) * 2017-09-27 2022-06-03 泰兴瑞泰化工有限公司 一种高纯乙氧基喹啉的吸附除杂方法
EP3743074A4 (de) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. Zusammensetzung und verfahren zur reduktion von thrombozytopenie über die verabreichung von plinabulin
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331846A (en) 1963-08-28 1967-07-18 Lilly Co Eli Metal catalyst process for converting alpha-amino-acetylenes to dihydroquinoline
IL51342A (en) * 1977-01-27 1980-11-30 Abic Ltd Ethoxyquin derivatives,their preparation and pharmaceutical and veterinary compositions comprising them
GB8816269D0 (en) * 1988-07-08 1988-08-10 Int Assn Of Fish Meal Manufact Compounds for use as anti-oxidants in fish meal/fish oil
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
JPH09301953A (ja) * 1996-03-12 1997-11-25 Sanwa Kagaku Kenkyusho Co Ltd マロン酸ジアミド誘導体及びその用途

Also Published As

Publication number Publication date
JP3159971B2 (ja) 2001-04-23
NO995175D0 (no) 1999-10-22
EA199900865A2 (ru) 2000-04-24
NZ500574A (en) 2000-08-25
NO995175L (no) 2000-04-25
DK0995743T3 (da) 2003-07-21
ES2196742T3 (es) 2003-12-16
FR2784988B1 (fr) 2002-09-20
JP2000128865A (ja) 2000-05-09
EA003272B1 (ru) 2003-02-27
US6350759B1 (en) 2002-02-26
KR20000029268A (ko) 2000-05-25
EP0995743A1 (de) 2000-04-26
AU5600999A (en) 2000-05-04
EP0995743B1 (de) 2003-04-02
AU753044B2 (en) 2002-10-03
KR100421074B1 (ko) 2004-03-04
CA2287046A1 (fr) 2000-04-23
PT995743E (pt) 2003-07-31
BR9905587A (pt) 2001-12-11
FR2784988A1 (fr) 2000-04-28
PL336139A1 (en) 2000-04-25
NO313590B1 (no) 2002-10-28
SI0995743T1 (en) 2003-08-31
EA199900865A3 (ru) 2000-10-30
ZA996667B (en) 2000-05-02
CN1255493A (zh) 2000-06-07
DE69906445T2 (de) 2004-04-08
CA2287046C (fr) 2003-12-02
DE69906445D1 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
ES2196742T3 (es) Derivados de dihidro- y tetrahidro-quineloina como antioxidantes medicos.
AU2002246728A1 (en) Carboline derivatives
ATE301653T1 (de) Pyrazolopyridine
ES2124167A1 (es) Nuevos derivados del bencimidazol con actividad antihistaminica.
DE60128003D1 (en) Camptothecin derivate
AU2002249890A1 (en) Carboline derivatives
NZ334954A (en) Substituted heterocycles as anti-tumor agents
WO2002048148A3 (en) Pyrazolopyridine derivatives
MY124078A (en) Eletriptan hydrobromide monohydrate
MY120237A (en) Method for the synthesis of quinoline derivatives
DE60201074D1 (en) Pyrazolopyridinderivate
IE863374L (en) Indoles.
MXPA04005151A (es) Compuestos terapeuticos.
AU6288700A (en) Novel benzo[f]naphthyridine, preparation and compositions containing them
AU1076802A (en) Selective glucocorticoid receptor agonists
DE69803648D1 (de) Metalloproteaseinhibitoren, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
ATE381544T1 (de) 1-aryl-4-cycloalk(en)ylpyrazole als antiparasitäre mittel
IL109396A0 (en) Pyrido (1,2,3-DE) quinoxaline derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
GB9906328D0 (en) 2-Substituted RNA preparation
AU6149800A (en) Pharmaceutical compositions containing 8-chloro-3(beta-diethylaminoethyl)-4-methyl-7-ethoxycarbonyl methoxy coumarin base and the salts thereof, with cholesterol-lowering activity
AU1773497A (en) Novel 2,3-benzodiazepine derivatives
IL147767A0 (en) Processes for the preparation of 2-arylvinyl alkyl ether and 1,4-diaryl-2-fluoro-2-butene compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0995743

Country of ref document: EP

REN Ceased due to non-payment of the annual fee